Black Diamond Therapeutics, Inc. Common Stock

Day range

$1.67 – $1.90

Open

$1.89

Prev close

$1.88

Volume

854.17K

Market cap

$108.01M

Shares out

57.45M

P/E

—

P/S

—

P/B

1.12

P/FCF

—

ROE

-44.3%

ROA

-34.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsJun 29, 2026

  On June 26, 2026, Black Diamond Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders in a virtual-only format via live webcast. Shannon Campbell and Kapil Dhingra were duly elected to the Board as Class III directors. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The Company's stockholders approved the non-binding, advisory vote on the compensation of the Company's named executive officers.

• Clinical trial resultsMay 21, 2026

  On May 21, 2026, the Company announced results from its Phase 2 trial of silevertinib in frontline ('1L') non-small cell lung cancer ('NSCLC') patients with epidermal growth factor receptor ('EGFR') non-classical mutations ('NCMs'). Key data highlights include: Preliminary median progression-free survival is 15.2 months (95% CI: 10.8, NE); Median duration of response ('DOR') had not been reached (95% CI: 7.0, NE); ORR (ORR by RECIST 1.1) and Disease Control Rate ('DCR') remained at 60% and 91%, respectively.

• Guidance issuance or updateDec 3, 2025

  The Company announced that its previously reported cash, cash equivalents and investments of approximately $135.5 million as of September 30, 2025 is now expected to be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second half of 2028.

• Annual meeting resultsJun 12, 2025

  Ali Behbahani, Garry E. Menzel and Samarth Kulkarni were duly elected to the Board as Class II directors. The results of the stockholders' vote with respect to the election of the Class II directors were as follows: [voting results table]. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

• Significant contract awardMar 19, 2025

  Under the License Agreement, the Company will receive an upfront payment of $70.0 million and will be eligible to receive up to $710.0 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales.

Days to cover

7.3

Short interest

4.78M

Avg volume

653.62K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• What's Going On With Black Diamond Therapeutics Stock Tuesday?
  positiveBenzinga· May 26, 2026
• Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
  positiveGlobeNewswire Inc.· May 22, 2026
• Black Diamond (BDTX) Q2 Loss Narrows 47%
  neutralThe Motley Fool· Aug 7, 2025
• Clarus (CLAR) Q2 Loss Beats Estimates
  neutralThe Motley Fool· Aug 1, 2025
• Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
  positiveGlobeNewswire Inc.· Mar 19, 2025